{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T03:47:31Z","timestamp":1794023251501,"version":"4.8.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T00:00:00Z","timestamp":1615766400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T00:00:00Z","timestamp":1615766400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s12032-021-01486-x","type":"journal-article","created":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T11:02:28Z","timestamp":1615806148000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":77,"title":["An updated review of epidemiology, risk factors, and management of male breast cancer"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0097-1793","authenticated-orcid":false,"given":"Noman Ahmed Jang","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Tirona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,15]]},"reference":[{"key":"1486_CR1","unstructured":"Cancer Statistics Center. American Cancer Society. 2020. Breast Statistics | American Cancer Society - Cancer Facts & Statistics. https:\/\/cancerstatisticscenter.cancer.org\/cancer-site\/Breast\/91Q4dqjU"},{"key":"1486_CR2","unstructured":"Surveillance, Epidemiology, and End Results Program. SEER cancer statistics review (CSR) 1975\u20132016. https:\/\/seer.cancer.gov\/csr\/1975_2016\/. Accessed 24 Oct 2019"},{"issue":"1","key":"1486_CR3","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/cncr.20312","volume":"101","author":"SH Giordano","year":"2004","unstructured":"Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN. Breast carcinoma in men: a population-based study. Cancer. 2004;101(1):51\u20137.","journal-title":"Cancer"},{"issue":"20","key":"1486_CR4","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1093\/jnci\/djn329","volume":"100","author":"LA Brinton","year":"2008","unstructured":"Brinton LA, Richesson DA, Gierach GL, Lacey JV Jr, Park Y, Hollenbeck AR, Schatzkin A. Prospective evaluation of risk factors for male breast cancer. J Natl Cancer Inst. 2008;100(20):1477\u201381.","journal-title":"J Natl Cancer Inst."},{"issue":"11","key":"1486_CR5","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/aje\/153.11.1071","volume":"153","author":"PA Newcomb","year":"2001","unstructured":"Newcomb PA, Trentham-Dietz A, Egan KM, Titus-Ernstoff L, Baron JA, Storer BE, Willett WC, Stampfer MJ. Fracture history and risk of breast and endometrial cancer. Am J Epidemiol. 2001;153(11):1071\u20138.","journal-title":"Am J Epidemiol."},{"issue":"1","key":"1486_CR6","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10549-009-0379-0","volume":"119","author":"LA Brinton","year":"2010","unstructured":"Brinton LA, Carreon JD, Gierach GL, McGlynn KA, Gridley G. Etiologic factors for male breast cancer in the US Veterans affairs medical care system database. Breast Cancer Res Treat. 2010;119(1):185\u201392.","journal-title":"Breast Cancer Res Treat."},{"issue":"6D","key":"1486_CR7","first-page":"4293","volume":"17","author":"R Hultborn","year":"1997","unstructured":"Hultborn R, Hanson C, K\u00f6pf I, Verbiene I, Warnhammar E, Weimarck A. Prevalence of Klinefelter\u2019s syndrome in male breast cancer patients. Anticancer Res. 1997;17(6D):4293\u20137.","journal-title":"Anticancer Res."},{"issue":"16","key":"1486_CR8","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/jnci\/dji240","volume":"97","author":"AJ Swerdlow","year":"2005","unstructured":"Swerdlow AJ, Schoemaker MJ, Higgins CD, Wright AF, Jacobs PA. Cancer incidence and mortality in men with Klinefelter syndrome: a cohort study. J Natl Cancer Inst. 2005;97(16):1204\u201310.","journal-title":"J Natl Cancer Inst."},{"issue":"1","key":"1486_CR9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/BF01830721","volume":"5","author":"DB Thomas","year":"1994","unstructured":"Thomas DB, Rosenblatt K, Jimenez LM, McTiernan A, Stalsberg H, Stemhagen A, Thompson WD, Curnen MG, Satariano W, Austin DF, Greenberg RS. Ionizing radiation and breast cancer in men (United States). Cancer Causes Control. 1994;5(1):9\u201314.","journal-title":"Cancer Causes Control"},{"issue":"2","key":"1486_CR10","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1289\/EHP151","volume":"125","author":"MP Little","year":"2016","unstructured":"Little MP, McElvenny DM. Male breast cancer incidence and mortality risk in the Japanese atomic bomb survivors\u2013differences in excess relative and absolute risk from female breast cancer. Environ Health Perspect. 2016;125(2):223\u20139.","journal-title":"Environ Health Perspect."},{"key":"1486_CR11","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1126\/science.7545954","volume":"7","author":"Y Miki","year":"1994","unstructured":"Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, Bell R. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;7:66\u201371.","journal-title":"Science"},{"issue":"6559","key":"1486_CR12","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/378789a0","volume":"378","author":"R Wooster","year":"1995","unstructured":"Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G, Barfoot R. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378(6559):789.","journal-title":"Nature"},{"issue":"1","key":"1486_CR13","first-page":"265","volume":"56","author":"DF Easton","year":"1995","unstructured":"Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers breast cancer linkage consortium. Am J Human Genet. 1995;56(1):265.","journal-title":"Am J Human Genet."},{"issue":"3","key":"1486_CR14","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1086\/301749","volume":"62","author":"D Ford","year":"1998","unstructured":"Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Human Genet. 1998;62(3):676\u201389.","journal-title":"Am J Human Genet."},{"issue":"8974","key":"1486_CR15","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/S0140-6736(95)91383-1","volume":"346","author":"S Thorlacius","year":"1995","unstructured":"Thorlacius S, Tryggvadottir L, Olafsdottir GH, Jonasson JG, Ogmundsdottir HM, Tulinius H, Eyfjord JE. Linkage to BRCA2 region in hereditary male breast cancer. Lancet. 1995;346(8974):544\u20135.","journal-title":"Lancet"},{"issue":"1","key":"1486_CR16","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1086\/513891","volume":"61","author":"DF Easton","year":"1997","unstructured":"Easton DF, Steele L, Fields P, Ormiston W, Averill D, Daly PA, McManus R, Neuhausen SL, Ford D, Wooster R, Cannon-Albright LA. Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. Am J Hum Genet. 1997;61(1):120.","journal-title":"Am J Hum Genet."},{"issue":"1","key":"1486_CR17","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/his.12862","volume":"68","author":"S Deb","year":"2016","unstructured":"Deb S, Lakhani SR, Ottini L, Fox SB. The cancer genetics and pathology of male breast cancer. Histopathology. 2016;68(1):110\u20138.","journal-title":"Histopathology"},{"issue":"7","key":"1486_CR18","first-page":"1367","volume":"58","author":"K Haraldsson","year":"1998","unstructured":"Haraldsson K, Loman N, Zhang QX, Johannsson O, Olsson H, Borg \u00c5. BRCA2 germ-line mutations are frequent in male breast cancer patients without a family history of the disease. Cancer Res. 1998;58(7):1367\u201371.","journal-title":"Cancer Res."},{"issue":"23","key":"1486_CR19","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1093\/jnci\/djm203","volume":"99","author":"YC Tai","year":"2007","unstructured":"Tai YC, Domchek S, Parmigiani G, Chen S. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2007;99(23):1811\u20134.","journal-title":"J Natl Cancer Inst."},{"issue":"5","key":"1486_CR20","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/(SICI)1097-0142(19990901)86:5<744::AID-CNCR4>3.0.CO;2-G","volume":"86","author":"HT Lynch","year":"1999","unstructured":"Lynch HT, Watson P, Narod SA. The genetic epidemiology of male breast carcinoma. Cancer. 1999;86(5):744\u20136.","journal-title":"Cancer"},{"issue":"23","key":"1486_CR21","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/jnci\/djj465","volume":"98","author":"HA Risch","year":"2006","unstructured":"Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Fan I, Tang J, Li S, Zhang S, Shaw PA, Narod SA. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin\u2013cohort study in Ontario, Canada. J Natl Cancer Inst. 2006;98(23):1694\u2013706.","journal-title":"J Natl Cancer Inst."},{"issue":"1","key":"1486_CR22","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/ng0594-103","volume":"7","author":"MR Stratton","year":"1994","unstructured":"Stratton MR, Ford D, Neuhasen S, Seal S, Wooster R, Friedman LS, King MC, Egilsson V, Devilee P, McManus R, Daly PA. Familial male breast cancer is not linked to the BRCA1 locus on chromosome 17q. Nat Genet. 1994;7(1):103.","journal-title":"Nat Genet."},{"key":"1486_CR23","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Genetic\/Familial High-risk Assessment: Breast and Ovarian, 2019 https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_screening.pdf."},{"key":"1486_CR24","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/ng879","volume":"31","author":"H Meijers-Heijboer","year":"2002","unstructured":"Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, Hollestelle A, Houben M, Crepin E, van Veghel-Plandsoen M, Elstrodt F, CHEK2-Breast Cancer Consortium MR. Low-penetrance susceptibility to breast cancer due to CHEK2 (*) 1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet. 2002;31:55\u20139.","journal-title":"Nat Genet."},{"issue":"11","key":"1486_CR25","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/ng1902","volume":"38","author":"S Seal","year":"2006","unstructured":"Seal S, Thompson D, Renwick A, Elliott A, Kelly P, Barfoot R, Chagtai T, Jayatilake H, Ahmed M, Spanova K, North B. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet. 2006;38(11):1239.","journal-title":"Nat Genet."},{"issue":"8","key":"1486_CR26","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/ng1837","volume":"38","author":"A Renwick","year":"2006","unstructured":"Renwick A, Thompson D, Seal S, Kelly P, Chagtai T, Ahmed M, North B, Jayatilake H, Barfoot R, Spanova K, McGuffog L. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet. 2006;38(8):873.","journal-title":"Nat Genet."},{"issue":"2","key":"1486_CR27","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/ng1959","volume":"39","author":"N Rahman","year":"2007","unstructured":"Rahman N, Seal S, Thompson D, Kelly P, Renwick A, Elliott A, Reid S, Spanova K, Barfoot R, Chagtai T, Jayatilake H. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet. 2007;39(2):165.","journal-title":"Nat Genet."},{"issue":"4","key":"1486_CR28","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/hmg\/ddi052","volume":"14","author":"A Shaag","year":"2005","unstructured":"Shaag A, Walsh T, Renbaum P, Kirchhoff T, Nafa K, Shiovitz S, Mandell JB, Welcsh P, Lee MK, Ellis N, Offit K. Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population. Hum Mol Genet. 2005;14(4):555\u201363.","journal-title":"Hum Mol Genet."},{"issue":"3","key":"1486_CR29","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1136\/jmg.38.3.159","volume":"38","author":"JD Fackenthal","year":"2001","unstructured":"Fackenthal JD, Marsh DJ, Richardson AL, Cummings SA, Eng C, Robinson BG, Olopade OI. Male breast cancer in Cowden syndrome patients with germline PTEN mutations. J Med Genet. 2001;38(3):159\u201364.","journal-title":"J Med Genet."},{"issue":"3","key":"1486_CR30","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/(SICI)1097-0142(19990201)85:3<629::AID-CNCR13>3.0.CO;2-V","volume":"85","author":"PE Goss","year":"1999","unstructured":"Goss PE, Reid C, Pintilie M, Lim R, Miller N. Male breast carcinoma: a review of 229 patients who presented to the princess Margaret hospital during 40 years: 1955\u20131996. Cancer. 1999;85(3):629\u201339.","journal-title":"Cancer"},{"issue":"3","key":"1486_CR31","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0960-9776(96)90058-2","volume":"5","author":"GG Ribeiro","year":"1996","unstructured":"Ribeiro GG, Swindell R, Harris M, Banerjee SS, Cramer A. A review of the management of the male breast carcinoma based on an analysis of 420 treated cases. Breast. 1996;5(3):141\u20136.","journal-title":"Breast"},{"issue":"1","key":"1486_CR32","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0002-9343(63)90044-5","volume":"34","author":"MJ Williams","year":"1963","unstructured":"Williams MJ. Gynecomastia: its incidence, recognition and host characterization in 447 autopsy cases. Am J Med. 1963;34(1):103\u201312.","journal-title":"Am J Med."},{"issue":"11","key":"1486_CR33","doi-asserted-by":"crossref","first-page":"S313","DOI":"10.1016\/j.jacr.2018.09.017","volume":"15","author":"BL Niell","year":"2018","unstructured":"Niell BL, Lourenco AP, Moy L, Baron P, Didwania AD, Heller SL, Holbrook AI, Le-Petross HT, Lewin AA, Mehta TS, Slanetz PJ. ACR Appropriateness Criteria\u00ae evaluation of the symptomatic male breast. J Am Coll Radiol. 2018;15(11):S313\u201320.","journal-title":"J Am Coll Radiol."},{"issue":"5","key":"1486_CR34","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0002-9610(98)00046-4","volume":"175","author":"J Vetto","year":"1998","unstructured":"Vetto J, Schmidt W, Pommier R, DiTomasso J, Eppich H, Wood W, Moseson D. Accurate and cost-effective evaluation of breast masses in males. Am J Surg. 1998;175(5):383\u20137.","journal-title":"Am J Surg."},{"issue":"2","key":"1486_CR35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cncr.10483","volume":"96","author":"PJ Westenend","year":"2002","unstructured":"Westenend PJ, Jobse C. Evaluation of fine-needle aspiration cytology of breast masses in males. Cancer Cytopathol. 2002;96(2):1\u20135.","journal-title":"Cancer Cytopathol."},{"key":"1486_CR36","unstructured":"NCCN Clinical Practice Guidelines in Oncology. NCCN guidelines for genetic\/ familial high-risk assessment: breast and ovarian. 2017 https:\/\/www.nccn.org\/professionals\/physiciangls\/default.aspx."},{"issue":"2","key":"1486_CR37","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3322\/caac.21388","volume":"67","author":"MB Amin","year":"2017","unstructured":"Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR, Winchester DP. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population based to a more personalized approach to cancer staging. CA A Cancer J Clin. 2017;67(2):93\u20139.","journal-title":"CA A Cancer J Clin."},{"issue":"4","key":"1486_CR38","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3816\/CBC.2005.n.033","volume":"6","author":"I Pappo","year":"2005","unstructured":"Pappo I, Wasserman I, Halevy A. Ductal carcinoma in situ of the breast in men: a review. Clin Breast Cancer. 2005;6(4):310\u20134.","journal-title":"Clin Breast Cancer"},{"issue":"4","key":"1486_CR39","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s10555-018-9761-x","volume":"37","author":"RA Leon-Ferre","year":"2018","unstructured":"Leon-Ferre RA, Giridhar KV, Hieken TJ, Mutter RW, Couch FJ, Jimenez RE, Hawse JR, Boughey JC, Ruddy KJ. A contemporary review of male breast cancer: current evidence and unanswered questions. Cancer Metastasis Rev. 2018;37(4):599\u2013614.","journal-title":"Cancer Metastasis Rev."},{"issue":"3","key":"1486_CR40","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/1066896916675953","volume":"25","author":"S Javidiparsijani","year":"2017","unstructured":"Javidiparsijani S, Rosen LE, Gattuso P. Male breast carcinoma: a clinical and pathological review. Int J Surg Pathol. 2017;25(3):200\u20135.","journal-title":"Int J Surg Pathol."},{"issue":"2","key":"1486_CR41","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/annonc\/mdx651","volume":"29","author":"F Cardoso","year":"2018","unstructured":"Cardoso F, Bartlett JMS, Slaets L, et al. Characterization of male breast cancer: results of the EORTC 10085\/TBCRC\/BIG\/NABCG international male breast cancer program. Ann Oncol. 2018;29(2):405\u201317. https:\/\/doi.org\/10.1093\/annonc\/mdx651.","journal-title":"Ann Oncol."},{"issue":"9","key":"1486_CR42","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1002\/cncr.27905","volume":"119","author":"M Chavez-MacGregor","year":"2013","unstructured":"Chavez-MacGregor M, Clarke CA, Lichtensztajn D, Hortobagyi GN, Giordano SH. Male breast cancer according to tumor subtype and race: a population-based study. Cancer. 2013;119(9):1611\u20137.","journal-title":"Cancer"},{"issue":"2","key":"1486_CR43","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2009.23.8162","volume":"28","author":"WF Anderson","year":"2010","unstructured":"Anderson WF, Jatoi I, Tse J, Rosenberg PS. Male breast cancer: a population-based comparison with female breast cancer. J Clin Oncol. 2010;28(2):232.","journal-title":"J Clin Oncol."},{"issue":"1","key":"1486_CR44","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1023\/B:BREA.0000010701.08825.2d","volume":"83","author":"WF Anderson","year":"2004","unstructured":"Anderson WF, Althuis MD, Brinton LA, Devesa SS. Is male breast cancer similar or different than female breast cancer? Breast Cancer Res Treat. 2004;83(1):77\u201386.","journal-title":"Breast Cancer Res Treat."},{"issue":"71","key":"1486_CR45","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejca.2016.10.038","volume":"1","author":"JP Leone","year":"2017","unstructured":"Leone JP, Leone J, Zwenger AO, Iturbe J, Leone BA, Vallejo CT. Locoregional treatment and overall survival of men with T1a, b, cN0M0 breast cancer: a population-based study. Eur J Cancer. 2017;1(71):7\u201314.","journal-title":"Eur J Cancer"},{"issue":"5","key":"1486_CR46","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.clbc.2013.05.004","volume":"13","author":"S Fogh","year":"2013","unstructured":"Fogh S, Kachnic LA, Goldberg SI, Taghian AG, Powell SN, Hirsch AE. Localized therapy for male breast cancer: functional advantages with comparable outcomes using breast conservation. Clin Breast Cancer. 2013;13(5):344\u20139.","journal-title":"Clin Breast Cancer"},{"issue":"4","key":"1486_CR47","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.jamcollsurg.2007.11.005","volume":"206","author":"LW Flynn","year":"2008","unstructured":"Flynn LW, Park J, Patil SM, Cody HS III, Port ER. Sentinel lymph node biopsy is successful and accurate in male breast carcinoma. J Am Coll Surg. 2008;206(4):616\u201321.","journal-title":"J Am Coll Surg."},{"issue":"2","key":"1486_CR48","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.ijrobp.2017.02.007","volume":"98","author":"MJ Abrams","year":"2017","unstructured":"Abrams MJ, Koffer PP, Wazer DE, Hepel JT. Postmastectomy radiation therapy is associated with improved survival in node-positive male breast cancer: a population analysis. Int J Radiat Oncol Biol Phys. 2017;98(2):384\u201391.","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"12","key":"1486_CR49","doi-asserted-by":"crossref","first-page":"117822341877068","DOI":"10.1177\/1178223418770687","volume":"19","author":"J Weir","year":"2018","unstructured":"Weir J, Zhao YD, Herman T, Algan \u00d6. Clinicopathologic features and radiation therapy utilization in patients with male breast cancer: a national cancer database study. Breast Cancer. 2018;19(12):1178223418770687.","journal-title":"Breast Cancer"},{"issue":"16","key":"1486_CR50","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1200\/JCO.19.03120","volume":"38","author":"MJ Hassett","year":"2020","unstructured":"Hassett MJ, Somerfield MR, Baker ER, Cardoso F, Kansal KJ, Kwait DC, Plichta JK, Ricker C, Roshal A, Ruddy KJ, Safer JD. Management of male breast cancer: ASCO guideline. J Clin Oncol. 2020;38(16):1849\u201363.","journal-title":"J Clin Oncol."},{"issue":"2","key":"1486_CR51","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s10549-012-2355-3","volume":"137","author":"H Eggemann","year":"2013","unstructured":"Eggemann H, Ignatov A, Smith BJ, Altmann U, von Minckwitz G, R\u00f6hl FW, Jahn M, Costa SD. Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients. Breast Cancer Res Treat. 2013;137(2):465\u201370.","journal-title":"Breast Cancer Res Treat."},{"issue":"9","key":"1486_CR52","first-page":"3027","volume":"85","author":"FJ Hayes","year":"2000","unstructured":"Hayes FJ, Seminara SB, DeCruz S, Boepple PA, Crowley WF Jr. Aromatase inhibition in the human male reveals a hypothalamic site of estrogen feedback. J Clin Endocrinol Metab. 2000;85(9):3027\u201335.","journal-title":"J Clin Endocrinol Metab."},{"issue":"8","key":"1486_CR53","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/1097-0142(19891015)64:8<1583::AID-CNCR2820640804>3.0.CO;2-Q","volume":"64","author":"HZ Patel","year":"1989","unstructured":"Patel HZ, Buzdar AU, Hortobagyi GN. Role of adjuvant chemotherapy in male breast cancer. Cancer. 1989;64(8):1583\u20135.","journal-title":"Cancer"},{"issue":"7","key":"1486_CR54","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3109\/02841869409083946","volume":"33","author":"MA Izquierdo","year":"1994","unstructured":"Izquierdo MA, Alonso C, de Andres L, Ojeda B. Male breast cancer report of a series of 50 cases. Acta Oncol. 1994;33(7):767\u201371.","journal-title":"Acta Oncol."},{"issue":"2","key":"1486_CR55","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10549-006-9363-0","volume":"103","author":"JM Walshe","year":"2007","unstructured":"Walshe JM, Berman AW, Vatas U, Steinberg SM, Anderson WF, Lippman ME, Swain SM. A prospective study of adjuvant CMF in males with node positive breast cancer: 20-year follow-up. Breast Cancer Res Treat. 2007;103(2):177\u201383.","journal-title":"Breast Cancer Res Treat."},{"issue":"1","key":"1486_CR56","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/00000421-198702000-00013","volume":"10","author":"CS Bagley","year":"1987","unstructured":"Bagley CS, Wesley MN, Young RC, Lippman ME. Adjuvant chemotherapy in males with cancer of the breast. Am J Clin Oncol. 1987;10(1):55\u201360.","journal-title":"Am J Clin Oncol."},{"issue":"14","key":"1486_CR57","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1200\/JCO.2017.76.8861","volume":"36","author":"SA Massarweh","year":"2018","unstructured":"Massarweh SA, Sledge GW, Miller DP, McCullough D, Petkov VI, Shak S. Molecular characterization and mortality from breast cancer in men. J Clin Oncol. 2018;36(14):1396.","journal-title":"J Clin Oncol."},{"issue":"1","key":"1486_CR58","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s10549-014-3138-9","volume":"148","author":"L Di Lauro","year":"2014","unstructured":"Di Lauro L, Vici P, Barba M, Pizzuti L, Sergi D, Rinaldi M, Di Benedetto A, Sperduti I, Shaaban AM, Speirs V, Mottolese M. Antiandrogen therapy in metastatic male breast cancer: results from an updated analysis in an expanded case series. Breast Cancer Res Treat. 2014;148(1):73\u201380.","journal-title":"Breast Cancer Res Treat."},{"issue":"6","key":"1486_CR59","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1093\/annonc\/mdp450","volume":"21","author":"J Doyen","year":"2010","unstructured":"Doyen J, Italiano A, Largillier R, Ferrero JM, Fontana X, Thyss A. Aromatase inhibition in male breast cancer patients: biological and clinical implications. Ann Oncol. 2010;21(6):1243\u20135.","journal-title":"Ann Oncol."},{"issue":"1","key":"1486_CR60","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s10549-014-3240-z","volume":"149","author":"F Zagouri","year":"2015","unstructured":"Zagouri F, Sergentanis TN, Chrysikos D, Dimopoulos MA, Psaltopoulou T. Fulvestrant and male breast cancer: a pooled analysis. Breast Cancer Res Treat. 2015;149(1):269\u201375.","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"1486_CR61","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1158\/1078-0432.CCR-19-2580","volume":"26","author":"S Wedam","year":"2020","unstructured":"Wedam S, Fashoyin-Aje L, Bloomquist E, Tang S, Sridhara R, Goldberg KB, Theoret MR, Amiri-Kordestani L, Pazdur R, Beaver JA. FDA approval summary: palbociclib for male patients with metastatic breast cancer. Clin Cancer Res. 2020;26(6):1208\u201312.","journal-title":"Clin Cancer Res."},{"key":"1486_CR62","unstructured":"NCCN Clinical Practice Guidelines in Oncology. NCCN guidelines for breast cancer. 2020 (NCCN Clinical Practice Guidelines in Oncology)"},{"issue":"1","key":"1486_CR63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-015-0143-8","volume":"34","author":"L Di Lauro","year":"2015","unstructured":"Di Lauro L, Pizzuti L, Barba M, Sergi D, Sperduti I, Mottolese M, Del Medico P, Belli F, Vici P, De Maria R, Maugeri-Sacc\u00e0 M. Efficacy of chemotherapy in metastatic male breast cancer patients: a retrospective study. J Exp Clin Cancer Res. 2015;34(1):1\u20135.","journal-title":"J Exp Clin Cancer Res."},{"key":"1486_CR64","doi-asserted-by":"crossref","first-page":"7251","DOI":"10.2147\/OTT.S209949","volume":"12","author":"L Chen","year":"2019","unstructured":"Chen L, Weng YM, Hu MX, Peng M, Song QB. Effects of HER2 status on the prognosis of male breast cancer: a population-based study. OncoTargets Therapy. 2019;12:7251.","journal-title":"OncoTargets Therapy"},{"key":"1486_CR65","first-page":"45","volume":"2","author":"L Ottini","year":"2010","unstructured":"Ottini L, Capalbo C, Rizzolo P, Silvestri V, Bronte G, Rizzo S, Russo A. HER2-positive male breast cancer: an update. Breast Cancer. 2010;2:45.","journal-title":"Breast Cancer"},{"issue":"3","key":"1486_CR66","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.critrevonc.2009.04.002","volume":"73","author":"B Cutuli","year":"2010","unstructured":"Cutuli B, Le-Nir CC, Serin D, Kirova Y, Gaci Z, Lemanski C, De Lafontan B, Zoubir M, Maingon P, Mignotte H, de Lara CT. Male breast cancer. Evolution of treatment and prognostic factors. Analysis of 489 cases. Crit Rev Oncol\/Hematol. 2010;73(3):246\u201354.","journal-title":"Crit Rev Oncol\/Hematol."},{"issue":"1","key":"1486_CR67","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/cncr.32472","volume":"126","author":"S Yadav","year":"2020","unstructured":"Yadav S, Karam D, Bin Riaz I, Xie H, Durani U, Duma N, Giridhar KV, Hieken TJ, Boughey JC, Mutter RW, Hawse JR. Male breast cancer in the United States: treatment patterns and prognostic factors in the 21st century. Cancer. 2020;126(1):26\u201336.","journal-title":"Cancer"},{"issue":"3","key":"1486_CR68","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s10549-015-3488-y","volume":"152","author":"JP Leone","year":"2015","unstructured":"Leone JP, Leone J, Zwenger AO, Iturbe J, Vallejo CT, Leone BA. Prognostic significance of tumor subtypes in male breast cancer: a population-based study. Breast Cancer Res Treat. 2015;152(3):601\u20139.","journal-title":"Breast Cancer Res Treat."},{"issue":"17","key":"1486_CR69","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/jnci\/94.17.1330","volume":"94","author":"A Auvinen","year":"2002","unstructured":"Auvinen A, Curtis RE, Ron E. Risk of subsequent cancer following breast cancer in men. J Natl Cancer Inst. 2002;94(17):1330\u20132.","journal-title":"J Natl Cancer Inst."},{"issue":"2","key":"1486_CR70","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1023\/A:1010639429207","volume":"66","author":"C Dong","year":"2001","unstructured":"Dong C, Hemminki K. Second primary breast cancer in men. Breast Cancer Res Treat. 2001;66(2):171.","journal-title":"Breast Cancer Res Treat."}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-021-01486-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-021-01486-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-021-01486-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T22:10:22Z","timestamp":1617315022000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-021-01486-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,15]]},"references-count":70,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["1486"],"URL":"https:\/\/doi.org\/10.1007\/s12032-021-01486-x","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,15]]},"assertion":[{"value":"23 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"IRB approval was not required for our study as no patient data were obtained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was not part of our study since it only includes review of literature.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"No human subjects or animals were involved in this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human and animal rights"}}],"article-number":"39"}}